4-{[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino}-butyric acid tert-butyl ester | 535924-18-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-{[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino}-butyric acid tert-butyl ester
• 英文别名: Tert-butyl 4-[[4-[(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)carbamoyl]pyridin-2-yl]methylamino]butanoate
• CAS: 535924-18-6
• 化学式: C₂₇H₃₅N₅O₅S
• 分子量: 541.671
• InChiKey: XOVMEVUHRJFFNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  4-{[4-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino}-butyric acid tert-butyl ester 在 三氟乙酸 作用下， 以95%的产率得到4-{[4-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl-carbamoyl)-pyridin-2-yl-methyl]-amino}-Butyric Acid
  参考文献：
  名称：

  Isonicotin- and nicotinamide derivatives of benzothiazoles

  摘要：

  本发明涉及具有以下公式的化合物1，其中R1、A和R如内部所述。本发明的化合物已被发现是腺苷受体配体。特别是，本发明的化合物对A2A受体具有亲和力，因此在治疗与该受体相关的疾病中非常有用。

  公开号：

  US20030134854A1

文献信息

• NICOTIN-OR ISONICOTIN BENZOTHIAZOLE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1448198A1

  公开（公告）日：2004-08-25
• US6620811B2
  申请人：——

  公开号：US6620811B2

  公开（公告）日：2003-09-16
• [EN] NICOTIN-OR ISONICOTIN BENZOTHIAZOLE DERIVATIVES<br/>[FR] DERIVES DE NICOTINE OU D'ISONICOTINE BENZOTHIAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003043636A1

  公开（公告）日：2003-05-30

  The present invention relates to compounds of the general formula(I) wherein R1 is phenyl, piperidin-1-yl or morpholinyl; A is-O-and R is-(CH¿2?)n-N(R')-C(O)-lower alkyl, -(CH2)n-O-lower alkyl, -(CH2)n-O-(CH2)n-O-lower alkyl, lower alkyl, -(CH2)n-morpholinyl, -(CH2)n-phenyl,-(CH2)n-N(R')2, (CH2)n-pyridinyl, -(CH2)n-CF3, (CH2)n-2-oxo-pyrrolidinyl or C4-6-cycloalkyl; R' is independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is-N(R')-and R is lower alkyl, C4-6-cycloalkyl, -(CH2)n-O-lower alkyl, -(CH2)n-pyridinyl, -(CH2)n-piperidinyl, -(CH2)n-phenyl, (CH2)n-N(R')-C(O)-lower alkyl, -(CH2)n-morpholinyl, or (CH2)n-N(R')2; R' and R' are independently from each other hydrogen or lower alkyl and n is 1 or 2; or A is CH2- and R is-N(R')-(CH2)m-O-lower alkyl, -N(R')2 S-lower alkyl, or is acetidinyl, pyrrolidinyl or piperidinyl, which optionally substituted by hydroxy or lower alkoxy or is morpholinyl, -N(R')-CH2)m-C4-6-cycloalkyl, -N(R')-(CH2m-C(O)O-lower alkyl, -N(R')-(CH2)m-C(O)OH, -2-oxo pyrrolidinyl, -N(R')-C(O)O-lower alkyl, -O(CH2)m-O-lower alkyl or alkoxy; R' is independently from each other hydrogen or lower alkyl and m is 1, 2 or 3; A is S- and R is lower alkyl; or A-R are together piperazinyl, substituted by lower alkyl, -C(O)-lower alkyl or a oxo group, or is piperidinyl, substituted by lower alkoxy or hydroxy, or is morpholinyl, substituted by lower alkyl, or is C4-6-cycloalkyl, -azetidin-1-yl, optionally substituted by hydroxy or lower alkoxy, thiomorpholine-1,1-dioxo, -tetrahydopyran or 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl; and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of general formula I are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they are therefore useful in the treatment of diseases related to this receptor.